New insights in the control of vascular permeability: Vascular endothelial-cadherin and other players

Current Opinion in Hematology

Volumn 22, Issue 3, 2015, Pages 267-272

  Trani, Marianna ^a   Dejana, Elisabetta ^a,b  

^a FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

endothelial cells; vascular endothelial cadherin; vascular permeability

Indexed keywords

G PROTEIN ALPHA 13; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN;

BLOOD VESSEL PERMEABILITY; CELL FUNCTION; ENZYME REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; CAPILLARY PERMEABILITY; HUMAN; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

CAPILLARY PERMEABILITY; ENDOTHELIUM, VASCULAR; HUMANS; SIGNAL TRANSDUCTION;

EID: 84928468707     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000137     Document Type: Review

References (40)

1. Stan RV, Tse D, Deharvengt SJ, et al. The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition. Dev Cell 2012; 23:1203-1218.
2. Dvorak AM, Feng D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem 2001; 49:419-432.
3. Giannotta M, Trani M, Dejana E. VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell 2013; 26:441-454.
4. Dejana E, Vestweber D. The role of VE-cadherin in vascular morphogenesis and permeability control. Prog Mol Biol Transl Sci 2013; 116:119-144.
5. Taddei A, Giampietro C, Conti A, et al. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol 2008; 10:923-934.
6. Van Itallie CM, Anderson JM. Architecture of tight junctions and principles of molecular composition. Semin Cell Dev Biol 2014; 36C:157-165.
7. Krug SM, Schulzke JD, Fromm M. Tight junction, selective permeability, and related diseases. Semin Cell Dev Biol 2014; 36C:166-176.
8. Turner JR, Buschmann MM, Romero-Calvo I, et al. The role of molecular remodeling in differential regulation of tight junction permeability. Semin Cell Dev Biol 2014; 36C:204-212.
9. Steed E, Balda MS, Matter K. Dynamics and functions of tight junctions. Trends Cell Biol 2010; 20:142-149.
10. Lampugnani MG, Orsenigo F, Gagliani MC, et al. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol 2006; 174:593-604.
11. Rudini N, Felici A, Giampietro C, et al. VE-cadherin is a critical endothelial regulator of TGF-beta signalling. EMBO J 2008; 27:993-1004.
12. Giampietro C, Taddei A, Corada M, et al. Overlapping and divergent signaling pathways of N-cadherin and VE-cadherin in endothelial cells. Blood 2012; 119:2159-2170.
13. Lambeng N, Wallez Y, Rampon C, et al. Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues. Circ Res 2005; 96:384-391.
14. Wallez Y, Cand F, Cruzalegui F, et al. Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene 2007; 26:1067-1077.
15. Corada M, Nyqvist D, Orsenigo F, et al. The Wnt/beta-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling. Dev Cell 2010; 18:938-949.
16. Orsenigo F, Giampietro C, Ferrari A, et al. Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo. Nat Commun 2012; 3:1208.
17. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-257.
18. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91:1071-1121.
19. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nature Rev Drug Discov 2011; 10:417-427.
20. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006; 8:1223-1234.
21. Monaghan-Benson E, Burridge K. The regulation of vascular endothelial growth factor-induced microvascular permeability requires Rac and reactive oxygen species. J Biol Chem 2009; 284:25602-25611.
22. Adam AP, Sharenko AL, Pumiglia K, et al. Src-induced tyrosine phosphorylation of VE-cadherin is not sufficient to decrease barrier function of endothelial monolayers. J Biol Chem 2010; 285:7045-7055.
23. Wessel F, Winderlich M, Holm M, et al. Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin. Nat Immunol 2014; 15:223-230.
24. Hatanaka K, Lanahan AA, Murakami M, et al. Fibroblast growth factor signaling potentiates VE-cadherin stability at adherens junctions by regulating SHP2. PloS One 2012; 7:e37600.
25. Weis S, Shintani S, Weber A, et al. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 2004; 113:885-894.
26. Sun Z, Li X, Massena S, et al. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. J Exp Med 2012; 209:1363-1377.
27. Tominaga J, Fukunaga Y, Abelardo E, et al. Defining the function of betacatenin tyrosine phosphorylation in cadherin-mediated cell-cell adhesion. Genes Cells 2008; 13:67-77.
28. Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 1997; 272:15442-15451.
29. Liang W, Kujawski M, Wu J, et al. Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res 2010; 16:924-935.
30. Chen XL, Nam JO, Jean C, et al. VEGF-induced vascular permeability is mediated by FAK. Dev Cell 2012; 22:146-157.
31. Jean C, Chen XL, Nam JO, et al. Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. J Cell Biol 2014; 204:247-263.
32. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002; 3:639-650.
33. Offermanns S, Mancino V, Revel JP, et al. Vascular system defects and impaired cell chemokinesis as a result of Galpha13 deficiency. Science 1997; 275:533-536.
34. Holinstat M, Mehta D, Kozasa T, et al. Protein kinase C alpha-induced p115RhoGEF phosphorylation signals endothelial cytoskeletal rearrangement. J Biol Chem 2003; 278:28793-28798.
35. Ruppel KM, Willison D, Kataoka H, et al. Essential role for Galpha13 in endothelial cells during embryonic development. Proc Natl Acad Sci USA 2005; 102:8281-8286.
36. Chen L, Zhang JJ, Rafii S, et al. Suppression of tumor angiogenesis by Galpha(13) haploinsufficiency. J Biol Chem 2009; 284:27409-27415.
37. Kaplan DD, Meigs TE, Casey PJ. Distinct regions of the cadherin cytoplasmic domain are essential for functional interaction with Galpha 12 and betacatenin. J Biol Chem 2001; 276:44037-44043.
38. Turm H,Maoz M, Katz V, et al. Protease-activated receptor-1 (PAR1) acts via a novel Galpha13-dishevelled axis to stabilize beta-catenin levels. J Biol Chem 2010; 285:15137-15148.
39. Gong H, Gao X, Feng S, et al. Evidence of a common mechanism of disassembly of adherens junctions through Galpha13 targeting of VE-cadherin. J Exp Med 2014; 211:579-591.
40. Spindler V, Schlegel N, Waschke J. Role of GTPases in control of microvascular permeability. Cardiovasc Res 2010; 87:243-253.